Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Trametinib (DMSO solvate)

Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate) ) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis[1][2]. This product is in solid form, a DMSO solvate, and a stable crystalline form.

Product Specifications

CAS Number

[1187431-43-1]

Product Name Alternative

GSK-1120212 (DMSO solvate) ; JTP-74057 (DMSO solvate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; MEK

Type

Reference compound

Related Pathways

Apoptosis; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Trametinib-DMSO-solvate.html

Purity

99.56

Solubility

DMSO : 3.33 mg/mL (ultrasonic)

Smiles

CN1C(C(C)=C(N(C(N(C2=O)C3CC3)=O)C4=CC=CC(NC(C)=O)=C4)C2=C1NC5=CC=C(C=C5F)I)=O.CS(C)=O

Molecular Formula

C28H29FIN5O5S

Molecular Weight

693.53

Precautions

H302, H315, H319, H335

References & Citations

[1]Yamaguchi T, et al. Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with HWA486. Inflamm Res, 2012, 61 (5), 445-454.|[2]Abe H, et al. Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate) . ACS Med Chem Lett. 2011 Feb 28;2 (4) :320-4.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

MEK1; MEK2

Citation 01

Cancer Cell. 2020 Mar 16;37 (3) :387-402.e7. |Cell Rep. 2021 Jul 20;36 (3) :109410.|Cell Rep. 2023 Dec 18;42 (12) :113586.|Faculty of Biology, University of Barcelona. 2020 Jan.|FASEB J. 2025 Aug 31;39 (16) :e70901.|Mol Cell. 2019 Jan 3;73 (1) :7-21.e7. |Patent. US20200046706A1.|Patent. US20210401844A1.|Patent. US20220162299A1.|Patent. US20220177583A1.|Physiol Behav. 2025 Aug 7:301:115059.|PLoS One. 2020 Sep 3;15 (9) :e0235824.|Sci Signal. 2018 Oct 30;11 (554) :eaar6795.|University of Leicester. 2023 Sep.|ACS Comb Sci. 2019 Dec 9;21 (12) :805-816.|Acta Pharmacol Sin. 2023 Jul;44 (7) :1475-1486.|Adv Healthc Mater. 2024 Dec;13 (32) :e2402685.|Adv Sci (Weinh) . 2023 Apr;10 (12) :e2201164.|Adv Sci (Weinh) . 2025 Aug 22:e08451.|Adv Sci (Weinh) . 2025 Jun 25:e15176.|Am J Dig Dis (Madison) . 2015;2 (2) :95-99.|Am J Respir Cell Mol Biol. 2019 Sep;61 (3) :355-366.|Anal Chem. 2024 Mar 19;96 (11) :4455-4462.|Angiogenesis. 2024 Nov;27 (4) :739-752.|Anticancer Res. 2025 Jun;45 (6) :2285-2295.|Aquaculture. 2023 Sep 23, 740148.|Aquaculture. 2024 Oct 15.|Arch Dermatol Res. 2025 Mar 1;317 (1) :514.|Biochem Biophys Rep. 2025 Jul 17:43:102164.|Biochem Biophys Rep. 2025 Sep 3:44:102235.|Biochem Biophys Res Commun. 2017 Aug 5;489 (4) :484-489.|Biochem Biophys Res Commun. 2018 Jan 8;495 (2) :1846-1850. |Biochem Biophys Res Commun. 2025 May 15:771:152027.|Biochem Pharmacol. 2025 Feb 7:116796.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomaterials. 2018 Sep;178:158-169.|Biomaterials. 2022 Oct:289:121800.|Biomolecules. 2021 Mar 30;11 (4) :518.|Biomolecules. 2023 Apr 25;13 (5) :740.|Biomolecules. 2025 Sep 30;15 (10) :1396.|bioRxiv. 2019 Sep.|bioRxiv. 2023 Oct 23:2023.10.20.563266.|bioRxiv. 2023 Oct 6.|bioRxiv. 2023 Sep 8.|bioRxiv. 2024 Apr 18:2023.08.31.555808.|bioRxiv. 2024 August 09.|bioRxiv. 2024 Dec 20:2024.12.19.629301.|bioRxiv. 2024 Dec 5:2024.11.29.625709.|bioRxiv. 2024 November 03.|bioRxiv. 2024 November 28.|bioRxiv. 2024 October 26.|bioRxiv. 2024 September 04.|bioRxiv. 2024 September 19.|bioRxiv. 2024 September 23.|bioRxiv. 2025 April 07.|bioRxiv. 2025 Aug 25:2025.08.21.671520.|bioRxiv. 2025 Jan 24:2025.01.22.634215.|bioRxiv. 2025 Jun 7:2025.06.04.657911.|bioRxiv. 2025 May 16.|bioRxiv. 2025 Nov 20:2025.11.20.689490.|bioRxiv. 2025 Oct 25.|bioRxiv. 2025 Sep 21.|Blood Cancer J. 2024 Aug 19;14 (1) :138.|Br J Cancer. 2023 Aug;129 (2) :249-265.|Cancer Biol Ther. 2019;20 (5) :653-665.|Cancer Cell. 2021 Aug 9;39 (8) :1135-1149.e8.|Cancer Cell. 2021 May 10;39 (5) :678-693.e11.|Cancer Cell. 2023 Dec 11;41 (12) :2083-2099.e9.|Cancer Cell. 2024 Jul 8;42 (7) :1286-1300.e8.|Cancer Commun (Lond) . 2025 Jun 10.|Cancer Discov. 2012 Oct;2 (10) :934-47.|Cancer Discov. 2015 Sep;5 (9) :960-71.|Cancer Discov. 2018 Mar;8 (3) :354-369.|Cancer Discov. 2020 Aug;10 (8) :1226-1239.|Cancer Discov. 2020 Jun;10 (6) :872-887.|Cancer Immunol Res. 2021 Feb;9 (2) :136-146.|Cancer Lett. 2017 Nov 1:408:43-54.|Cancer Lett. 2024 Jun 5:217007.|Cancer Res. 2022 Jul 18;82 (14) :2552-2564.|Cancer Res. 2024 Nov 4;84 (21) :3629-3639.|Cancer Res. 2025 Apr 15;85 (8) :1368-1389.|Cancers (Basel) . 2021 Feb 2;13 (3) :581.|Cancers (Basel) . 2022 Mar 11;14 (6) :1451.|Cancers (Basel) . 2023 Apr 13;15 (8) :2280.|Cancers (Basel) . 2024 Aug 7;16 (16) :2785.|Carcinogenesis. 2025 Aug 21:bgaf048.|Cell Biol Int. 2025 Jan;49 (1) :55-67.|Cell Chem Biol. 2018 Aug 16;25 (8) :996-1005.e4.|Cell Death Differ. 2020 May;27 (5) :1520-1538. |Cell Death Dis. 2022 Oct 3;13 (10) :844.|Cell Death Dis. 2024 Nov 13;15 (11) :821.|Cell Death Dis. 2025 Jul 1;16 (1) :482.|Cell Death Dis. 2025 Oct 6;16 (1) :682.|Cell Death Discov. 2023 Sep 19;9 (1) :347.|Cell Genom. 2025 Jul 9;5 (7) :100881.|Cell Metab. 2019 Jan 8;29 (1) :141-155.e9. |Cell Metab. 2025 May 6;37 (5) :1171-1188.e9.|Cell Mol Life Sci. 2023 Mar 18;80 (4) :100.|Cell Oncol (Dordr) . 2022 Dec;45 (6) :1401-1419.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep. 2025 Sep 1;44 (9) :116139.|Cell Rep. 2019 Jul 2;28 (1) :119-131.e4. |Cell Signal. 2024 Sep 16:111415.|Cell Syst. 2019 Jul 24;9 (1) :35-48.e5. |Cell Syst. 2020 Jan 22;10 (1) :66-81.e11.|Cell Syst. 2020 Nov 18;11 (5) :478-494.e9.|Cell. 2024 Feb 1;187 (3) :624-641.e23.|Cell. 2024 Jan 4;187 (1) :166-183.e25.|Cell. 2018 Aug 9;174 (4) :843-855.e19.|Cells. 2022 Aug 4;11 (15) :2402.|Chem Biol Interact. 2025 Oct 22:420:111712.|Clin Cancer Res. 2014 Nov 1;20 (21) :5483-95. |Clin Cancer Res. 2022 Sep 1;28 (17) :3836-3849.|Clin Cancer Res. 2023 Apr 3;29 (7) :1232-1242.|Commun Biol. 2025 Apr 24;8 (1) :656.|Comput Struct Biotechnol J. 2019 Feb 8:17:352-361.|Cornell University. 2025.|Dis Model Mech. 2023 Mar 1;16 (3) :dmm049769.|Discov Oncol. 2025 Nov 19;16 (1) :2129.|EBioMedicine. 2020 Jan;51:102583.|EBioMedicine. 2023 Jan:87:104397.|EMBO Mol Med. 2025 Dec;17 (12) :3377-3406.|EMBO Rep. 2025 Jun 17.|Endocrinology. 2024 Sep 26;165 (11) :bqae123.|Eur J Cancer. 2018 Aug:99:37-48.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Exp Mol Med. 2023 Oct;55 (10) :2177-2189.|FEBS Lett. 2024 Dec;598 (24) :3053-3070.|Front Cell Dev Biol. 2018 Sep 25:6:111.|Front Oncol. 2021 Jul 13:11:704042.|Genes Dis. 2021 Jul 1;9 (6) :1650-1661.|Geroscience. 2024 Apr;46 (2) :1861-1879.|Harvard Medical School LINCS LIBRARY|Inflammation. 2023 Aug;46 (4) :1445-1457.|Int Immunopharmacol. 2025 Apr 16:155:114626.|Int J Cancer. 2019 Mar 15;144 (6) :1379-1390.|Int J Mol Sci. 2022 Nov 19;23 (22) :14385.|Int J Mol Sci. 2022 Oct 20;23 (20) :12587.|Int J Mol Sci. 2022 Oct 8;23 (19) :11939.|Int J Mol Sci. 2023 Mar 13;24 (6) :5452.|Int J Mol Sci. 2025 Jun 19;26 (12) :5873.|iScience. 2025 Aug 6;28 (9) :113310.|J Cardiothorac Surg. 2021 May 10;16 (1) :127.|J Cell Biochem. 2016 Jun;117 (6) :1340-51. |J Cell Sci. 2019 May 31;132 (11) :jcs224071.|J Clin Invest. 2023 Jan 17;133 (2) :e153470.|J Clin Toxicol 2014, 4:5|J Clin Toxicol. 2014 October 4, 4:5.|J Exp Clin Cancer Res. 2018 Sep 5;37 (1) :218.|J Exp Clin Cancer Res. 2023 Apr 19;42 (1) :92.|J Exp Clin Cancer Res. 2024 Jun 18;43 (1) :171.|J Exp Med. 2024 Mar 4;221 (3) :e20232028.|J Hepatol. 2021 Aug;75 (2) :363-376.|J Invest Dermatol. 2022 Mar;142 (3 Pt A) :613-623.e7.|J Invest Dermatol. 2023 Oct;143 (10) :1993-2006.e10.|J Med Virol. 2025 Mar;97 (3) :e70267.|J Transl Med. 2022 Jun 7;20 (1) :263.|J Transl Med. 2023 Jan 9;21 (1) :9.|J Transl Med. 2024 May 13;22 (1) :450.|J Transl Med. 2025 Jun 17;23 (1) :660.|J Vasc Res. 2023 Feb 2.|JCI Insight. 2024 Nov 22;9 (22) :e179729.|JCO Precis Oncol. 2024 Apr:8:e2300538.|Johns Hopkins University. 2025.|Leuk Lymphoma. 2021 Feb;62 (2) :337-347.|mBio. 2024 Feb 14;15 (2) :e0319723.|medRxiv. 2023 Nov 13.|Mil Med Res. 2023 Dec 20;10 (1) :68.|Mol Cancer Ther. 2016 Aug;15 (8) :1859-69. |Mol Cancer Ther. 2025 Nov 20.|Mol Cancer. 2023 May 20;22 (1) :86.|Mol Cancer. 2024 Sep 20;23 (1) :204.|Mol Carcinog. 2024 Apr 17|Mol Carcinog. 2025 Jul;64 (7) :1247-1263.|Mol Pharmacol. 2019 Dec;96 (6) :862-870.|Mol Psychiatry. 2022 Nov;27 (11) :4770-4780.|Mol Syst Biol. 2024 Jan;20 (1) :28-55.|Mol Ther Nucleic Acids. 2024 Jul 19;35 (3) :102283.|Nat Biomed Eng. 2018 Aug;2 (8) :578-588.|Nat Cancer. 2025 Jul;6 (7) :1263-1282.|Nat Cell Biol. 2023 Jan;25 (1) :159-169.|Nat Commun. 2020 Aug 13;11 (1) :4053.|Nat Commun. 2020 May 11;11 (1) :2333.|Nat Commun. 2020 Oct 29;11 (1) :5463.|Nat Commun. 2021 Aug 25;12 (1) :5058.|Nat Commun. 2023 May 19;14 (1) :2859.|Nat Commun. 2024 Mar 21;15 (1) :2551.|Nat Commun. 2024 May 7;15 (1) :3805.|Nat Commun. 2025 Apr 30;16 (1) :4060.|Nat Commun. 2025 Jul 8;16 (1) :6270.|Nat Commun. 2025 Nov 11;16 (1) :9913.|Nat Commun. 2019 Jan 17;10 (1) :296.|Nature. 2025 Jun;642 (8066) :201-211.|Neuro Oncol. 2019 Mar 18;21 (4) :486-497. |Neuro Oncol. 2025 Mar 14:noaf068.|NPJ Precis Oncol. 2025 May 27;9 (1) :156.|Oncogene. 2024 May 17.|Oncogenesis. 2019 Nov 4;8 (11) :65. |Oncol Lett. 2017 Dec;14 (6) :6863-6868.|Oncol Lett. 2022 Feb;23 (2) :51.|Oncol Rep. 2018 Dec; 40 (6) : 3313–3322.|Oncotarget. 2015 Oct 13;6 (31) :31313-22. |Oncotarget. 2017 Feb 28;8 (9) :14835-14846. |Oncotarget. 2020 Nov 3;11 (44) :3921-3932.|Patent. US20180161326A1.|Patent. US20180169102A1.|Patent. US20180291421A1.|Patent. US20200276189A1.|Patent. US20200291111A1.|Patent. US20200308623A1.|Patent. US20200354680A1.|Patent. US20210008047A1.|Patent. US20210010089A1.|Patent. US20220265657A1.|Patent. US20220372134A1.|Patent. US20230049752A1.|Patent. US20230068698A1.|Patent. US20230158019A1.|Patent. US20240140945A1.|Patent. US20240239801A1.|Patent. US20240366605A1|Patent. US20240366605A1.|Patent. WO2019056023A2.|Pharmacol Res. 2025 Dec:222:108027.|Phytomedicine. 2024 Apr:126:155208.|Phytomedicine. 2025 Jan 29:139:156437.|Phytomedicine. 2025 Oct:146:157151.|PLoS Biol. 2020 Jul 17;18 (7) :e3000778.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Preprints. 2024 Jul 8.|Preprints. 2025 Apr 08.|Preprints. 2025 Nov 18.|Proc Natl Acad Sci U S A. 2018 Oct 9;115 (41) :E9570-E9579. |Proc Natl Acad Sci U S A. 2019 Mar 5;116 (10) :4508-4517.|Res Sq. 2025 Apr 14.|Research Square Preprint. 2020 Jun.|Research Square Preprint. 2021 Oct.|Research Square Preprint. 2023 Jul 10.|Research Square Preprint. 2023 May 16.|Research Square Preprint. 2024 Nov 03.|Research Square Preprint. 2024 Nov 06.|Research Square Preprint. 2024 Nov 26.|Research Square Preprint. 2024 Oct 10.|Research Square Print. October 10th, 2022.|Sci Data. 2024 Sep 19;11 (1) :1024.|Sci Rep. 2016 Oct 19;6:35531.|Sci Rep. 2017 Mar 28;7:45332.|Sci Rep. 2022 Nov 5;12 (1) :18811.|Sci Rep. 2025 Oct 16;15 (1) :36227.|Sci Signal. 2025 Sep 2;18 (902) :eadw3231.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Sci Transl Med. 2021 Jan 27;13 (578) :eaba7308.|SSRN. 2023 Aug 9.|SSRN. 2025 May 30.|SSRN. 2025 Nov 14.|Stem Cell Reports. 2016 Jan 12;6 (1) :74-84.|Stem Cell Reports. 2017 Dec 12;9 (6) :1948-1960.|Technical University of Munich. 2024.|Theranostics. 2022 Oct 3;12 (16) :7051-7066.|Theranostics. 2020 Feb 18;10 (8) :3579-3593. |Toxicology. 2024 May:504:153807.|Transpl Immunol. 2025 Jan 30:102183.|University of California. 2023 Feb.|University of Düsseldorf. 2024.|University of Otago. 2025 Oct 7.|University of Puerto Rico. 2024 Jun.|Vet J. 2024 Dec.|Viruses. 2021 Sep 3;13 (9) :1758.

Available Sizes

More Discoveries

Explore Other Products

Browse additional items from our catalog

Rabgef1 ORF Vector (Mouse) (pORF)
ORF055472 1.0 µg DNA

Rabgef1 ORF Vector (Mouse) (pORF)

Sign In for Pricing
View Details
UBTD2 Antibody
ABD8733 100 µg

UBTD2 Antibody

Sign In for Pricing
View Details
CLPP Rabbit Polyclonal Antibody
E28PN5759 100 µL

CLPP Rabbit Polyclonal Antibody

Sign In for Pricing
View Details
Propionyl Coenzyme A Carboxylase Beta (PCCb), Recombinant, Human, His-Tag
051535-01 10 µg

Propionyl Coenzyme A Carboxylase Beta (PCCb), Recombinant, Human, His-Tag

Sign In for Pricing
View Details
Propionyl Coenzyme A Carboxylase Beta (PCCb), Recombinant, Human, His-Tag
051535-02 50 µg

Propionyl Coenzyme A Carboxylase Beta (PCCb), Recombinant, Human, His-Tag

Sign In for Pricing
View Details
Propionyl Coenzyme A Carboxylase Beta (PCCb), Recombinant, Human, His-Tag
051535-03 100 µg

Propionyl Coenzyme A Carboxylase Beta (PCCb), Recombinant, Human, His-Tag

Sign In for Pricing
View Details